Predictors of Successful Cardioversion with Vernakalant in Patients with Recent-Onset Atrial Fibrillation.

Research output: Contribution to journalArticle

Abstract

Vernakalant is a novel atrial-selective antiarrhythmic drug able to convert recent-onset atrial fibrillation (AF) with reportedly low proarrhythmic risk. Successful cardioversion predictors are largely unknown. We sought to evaluate clinical and electrocardiographic predictors of cardioversion of recent-onset AF with vernakalant.

Details

Authors
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cardiac and Cardiovascular Systems
Original languageEnglish
Pages (from-to)140-147
JournalAnnals of Noninvasive Electrocardiology
Volume20
Issue number2
StatePublished - 2015
Peer-reviewedYes

Related research output

Natalia Mochalina 2017 Lund: Lund University, Faculty of Medicine. 81 p.

Research output: ThesisDoctoral Thesis (compilation)

View all (1)